Date of dispatch of this notice: 22/11/2018
External Reference: 2018-249274
TED Reference: 2018/S 228-522055
Contract award notice
Information
Published
Contract award notice
Cached Version
Contract award notice
Results of the procurement procedure
Directive 2014/24/EU
Section I: Contracting authority
I.1)
Name and addresses
The Health Research Board
N/A
67-72 Grattan House
Dublin 2
Lower Mount St
IE
Contact person:
Dara Murphy
Telephone:
+353 12345215
E-mail:
dmurphy@hrb.ie
NUTS code:
IE -
IRELAND
Main address:
www.hrb.ie
Address of the buyer profile:
https://irl.eu-supply.com/ctm/Company/CompanyInformation/Index/261
I.4)
Type of the contracting authority
Ministry or any other national or federal authority, including their regional or local subdivisions
I.5)
Main activity
Health
Section II: Object
II.1)
Scope of the procurement
II.1.1)
Title
Survey to determine the prevalence of the use of illicit drugs, alcohol, prescription drugs and gambling in the general population
Reference number:
HRB 2018 - Gen Pop Survey
II.1.2)
Main CPV code
79311200
-
Survey conduction services
II.1.3)
Type of contract
Services
II.1.4)
Short description
General Population Survey 2018/19
Prevalence and patterns of drug use among the general population, measured by probabilistic surveys of the adult and school population, is one of five EMCDDA key indicators that assess the drugs situation and allow monitoring of progress towards EU and Member State drug policy targets. The aim of this key indicator is to provide valid, reliable and comparable information on the extent, the distribution and the patterns of drug use in the general population (adults and young people), the characteristics of drug users and their perceptions. Each Member State is required to complete a regular survey to estimate national drug use prevalence and Ireland has conducted four of these general population surveys (2002/03, 2006/07, 20010/11 and 2014/15).
Prevalence and patterns of drug use among the general population, measured by probabilistic surveys of the adult and school population, is one of five EMCDDA key indicators that assess the drugs situation and allow monitoring of progress towards EU and Member State drug policy targets. The aim of this key indicator is to provide valid, reliable and comparable information on the extent, the distribution and the patterns of drug use in the general population (adults and young people), the characteristics of drug users and their perceptions. Each Member State is required to complete a regular survey to estimate national drug use prevalence and Ireland has conducted four of these general population surveys (2002/03, 2006/07, 20010/11 and 2014/15).
II.1.6)
Information about lots
This contract is divided into lots:
no
II.1.7)
Total value of the procurement
Value excluding VAT:
574675.00
EUR
II.2)
Description
II.2.2)
Additional CPV code(s)
79311000
-
Survey services
79311100
-
Survey design services
II.2.3)
Place of performance
NUTS code:
IE -
IRELAND
II.2.4)
Description of the procurement
The Health Research Board (HRB) is the lead agency in Ireland supporting and funding health research. We provide funding, maintain health information systems and conduct research linked to national health priorities. Our aim is to improve people's health, build health research capacity and make a significant contribution to Ireland's knowledge economy. Our latest Corporate Strategy clearly outlines how we hope to achieve this working in partnership with other organizations.
General Population Survey 2018/19
Prevalence and patterns of drug use among the general population, measured by probabilistic surveys of the adult and school population, is one of five EMCDDA key indicators that assess the drugs situation and allow monitoring of progress towards EU and Member State drug policy targets. The aim of this key indicator is to provide valid, reliable and comparable information on the extent, the distribution and the patterns of drug use in the general population (adults and young people), the characteristics of drug users and their perceptions. Each Member State is required to complete a regular survey to estimate national drug use prevalence and Ireland has conducted four of these general population surveys (2002/03, 2006/07, 20010/11 and 2014/15).1 Previous surveys were conducted simultaneously in Ireland and Northern Ireland (on behalf of the Public Health Information and Research Branch (PHIRB), within the Department of Health, Social Services and Public Safety). The 2018/19 survey will be conducted in Ireland only.
1. Survey brief
The Health Research Board will commission a fifth survey, to be completed between September 2018 and April 2019. The survey will require a nationally representative proability sample of the persons aged 15 years and over and resident in households in Ireland. The sample size will be in the order of 8,302. The survey will use a pre-prepared questionnaire and interviews will be conducted face-to-face in respondents’ homes using CAPI
General Population Survey 2018/19
Prevalence and patterns of drug use among the general population, measured by probabilistic surveys of the adult and school population, is one of five EMCDDA key indicators that assess the drugs situation and allow monitoring of progress towards EU and Member State drug policy targets. The aim of this key indicator is to provide valid, reliable and comparable information on the extent, the distribution and the patterns of drug use in the general population (adults and young people), the characteristics of drug users and their perceptions. Each Member State is required to complete a regular survey to estimate national drug use prevalence and Ireland has conducted four of these general population surveys (2002/03, 2006/07, 20010/11 and 2014/15).1 Previous surveys were conducted simultaneously in Ireland and Northern Ireland (on behalf of the Public Health Information and Research Branch (PHIRB), within the Department of Health, Social Services and Public Safety). The 2018/19 survey will be conducted in Ireland only.
1. Survey brief
The Health Research Board will commission a fifth survey, to be completed between September 2018 and April 2019. The survey will require a nationally representative proability sample of the persons aged 15 years and over and resident in households in Ireland. The sample size will be in the order of 8,302. The survey will use a pre-prepared questionnaire and interviews will be conducted face-to-face in respondents’ homes using CAPI
II.2.5)
Award criteria
Criteria below
Quality criterion
-
Name:
Experience in managing large population surveys
/
Weighting:
35%
Quality criterion
-
Name:
Qualifications of staff assigned to this project
/
Weighting:
10%
Quality criterion
-
Name:
Ability to deliver key outputs to a tight deadline
/
Weighting:
10%
Quality criterion
-
Name:
Understanding of the requirements of the contract and feasibility of the proposed plan
/
Weighting:
10%
Quality criterion
-
Name:
Clarity in outlining the proposed plan, including details around milestones and data analysis.
/
Weighting:
10
Price
-
Weighting:
25%
II.2.11)
Information about options
Options:
no
II.2.13)
Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
no
Section IV: Procedure
IV.1)
Description
IV.1.1)
Type of procedure
Open procedure
IV.1.8)
Information about the Government Procurement Agreement (GPA)
The procurement is covered by the Government Procurement Agreement: no
IV.2)
Administrative information
IV.2.1)
Previous publication concerning this procedure
Notice number in the OJ S: 2018/S 096-219063
Section V: Award of contract
Contract No: 1
Title: Survey to determine the prevalence of the use of illicit drugs, alcohol, prescription drugs and gambling in the general population
V.2)
Award of contract
V.2.1)
Date of conclusion of the contract
28/09/2018
V.2.2)
Information about tenders
Number of tenders received:
4
Number of tenders received by electronic means:
4
The contract has been awarded to a group of economic operators
:
noV.2.3)
Name and address of the contractor
Ipsos MRBI / MRBI Market Research Ltd
9701145N
Block 3 Blackrock Business Park
Co. Dublin
Carysfort Avenue, Bl
IE
Telephone:
+353 14389048
E-mail:
kieran.oleary@ipsos.com
NUTS code:
IE -
IRELAND
Internet address:
http://www.ipsosmrbi.com
The contractor is an SME : no
V.2.4)
Information on value of the contract/lot (excluding VAT)
Total value of the contract/lot:
574675.00
EUR
Section VI: Complementary information
VI.4)
Procedures for review
VI.4.1)
Review body
High Court
Chief Registrar, The Four Courts
Dublin
7
IE
Telephone:
+353 18886000
E-mail:
highcourtcentraloffice@courts.ie